Spruce Biosciences, Inc. (NASDAQ:SPRB) Financings
Financings
| Raise | Date |
|---|---|
| Strategic investment Announced: US$5.5M Buyers: Cure Sanfilippo Foundation (part of a combined $5.5 million strategic investment); National MPS Society (part of a combined $5.5 million strategic investment) Use of proceeds: Partially fund the TA-ERT Expanded Access Program to broaden patient access to TA-ERT for Sanfilippo Syndrome Type B | Aug 12, 2026 |
| Public offering of common stock or pre-funded warrants Announced: Leerink Partners +4 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), Jones, Craig-Hallum | Apr 20, 2026 |
| Private placement of common stock and pre-funded warrants Announced: about US$50M · US$68 a share · Leerink Partners +3 Dealers: Leerink Partners, Citizens Capital Markets, H.C. Wainwright & Co., Oppenheimer & Co. Use of proceeds: Advance tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B through a BLA submission in Q1 2026 and potential U.S. launch in late 2026 | Oct 8, 2025 |